Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $681,671.48 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson sold 10,562 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $64.54, for a total transaction of $681,671.48. Following the completion of the sale, the director now directly owns 32,070 shares of the company’s stock, valued at $2,069,797.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Cytokinetics Stock Up 0.8 %

Shares of Cytokinetics stock opened at $65.34 on Friday. Cytokinetics, Incorporated has a 52-week low of $25.98 and a 52-week high of $110.25. The company’s 50-day simple moving average is $69.91 and its 200-day simple moving average is $59.99. The firm has a market cap of $6.83 billion, a price-to-earnings ratio of -11.99 and a beta of 0.68.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.35). The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $7.62 million. During the same quarter in the prior year, the firm earned ($1.45) EPS. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. Equities research analysts anticipate that Cytokinetics, Incorporated will post -4.5 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTK. Fifth Third Bancorp grew its position in Cytokinetics by 94.1% during the first quarter. Fifth Third Bancorp now owns 656 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 318 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Cytokinetics by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,463 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 1,209 shares during the period. GAMMA Investing LLC acquired a new position in Cytokinetics during the fourth quarter worth about $80,000. Sage Rhino Capital LLC acquired a new position in Cytokinetics during the fourth quarter worth about $204,000. Finally, Caprock Group LLC acquired a new position in Cytokinetics during the fourth quarter worth about $216,000.

Wall Street Analyst Weigh In

CYTK has been the subject of a number of research reports. Truist Financial reissued a “buy” rating and issued a $86.00 price target on shares of Cytokinetics in a research report on Monday, April 8th. Mizuho reduced their target price on shares of Cytokinetics from $103.00 to $99.00 and set a “buy” rating for the company in a report on Wednesday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of Cytokinetics in a report on Wednesday, February 28th. Oppenheimer reaffirmed an “outperform” rating and issued a $107.00 target price on shares of Cytokinetics in a report on Monday, March 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $108.00 target price on shares of Cytokinetics in a report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Cytokinetics presently has an average rating of “Moderate Buy” and an average target price of $79.33.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.